生物可吸收支架极晚期血栓形成机制:INVEST注册研究
INVEST注册研究纳入19个中心36例患者38处病变,用OCT解析生物可吸收支架极晚期血栓形成(VLScT)机制。VLScT中位发生于置入后20个月,83%患者仅服阿司匹林;主要机制为支架不连续(42.1%),其次为贴壁不良和新动脉粥样硬化(各18.4%)。
要点
- VLScT中位发生于置入后20个月,多数患者仅服阿司匹林单药治疗。
- 支架不连续是VLScT首要机制(42.1%),提示不利的降解相关过程。
- 血栓处支架不连续、贴壁不良及未覆盖支柱的比值比均显著高于非血栓区域。
核心结论
- VLScT的主要机制为支架不连续,提示不利的吸收相关过程,其次为贴壁不良和新动脉粥样硬化。
- 支架设计改良和优化置入能否降低VLScT风险尚待确定。
研究设计与样本
- INVEST为国际多中心独立OCT注册研究,纳入2013年6月至2017年5月间19个中心的36例VLScT患者共38处病变。
- 所有患者均接受OCT检查以评估VLScT机制。
主要发现
- VLScT中位发生于置入后20个月(四分位距16至27个月)。
- 发生VLScT时83%患者接受阿司匹林单药治疗,17%接受双联抗血小板治疗。
- VLScT机制依次为支架不连续42.1%、贴壁不良18.4%、新动脉粥样硬化18.4%、膨胀不全或支架回缩10.5%、未覆盖支柱5.3%、边缘相关疾病进展2.6%。
- 血栓区域支架不连续(OR 110,95%CI 73.5至173,p<0.001)、贴壁不良支柱(OR 17.0,95%CI 14.8至19.7,p<0.001)及未覆盖支柱(OR 7.3,95%CI 6.2至8.8,p<0.001)均较非血栓区域更常见。
- 16例支架不连续患者中2例在VLScT前有OCT证据显示支架支柱环形贴壁且组织覆盖极少。
临床怎么用
- 对生物可吸收支架置入后极晚期出现血栓事件的患者,OCT检查有助于识别支架不连续、贴壁不良等机制。
- VLScT多发生于阿司匹林单药治疗期间,提示需关注该阶段的血栓风险。
局限性
- 样本量较小(36例患者38处病变),机制分布和比值比的稳健性可能受限。
- 仅16例支架不连续患者中2例有VLScT前序OCT资料,纵向证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Very late scaffold thrombosis (VLScT) occurs more frequently after bioresorbable scaffold (Absorb BVS 1.1, Abbott Vascular, Santa Clara, California) implantation than with metallic everolimus-eluting stents. OBJECTIVES: The purpose of this study was to elucidate mechanisms underlying VLScT as assessed by optical coherence tomography (OCT). METHODS: The INVEST (Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis) registry is an international consortium of investigators who used OCT to examine patients with VLScT. RESULTS: Between June 2013 and May 2017, 36 patients with 38 lesions who had VLScT underwent OCT at 19 centers. VLScT occurred at a median of 20 months (interquartile range: 16 to 27 months) after implantation. At the time of VLScT, 83% of patients received aspirin monotherapy and 17% received dual-antiplatelet therapy. The mechanisms underlying VLScT were (in descending order) scaffold discontinuity (42.1%), malapposition (18.4%), neoatherosclerosis (18.4%), underexpansion or scaffold recoil (10.5%), uncovered struts (5.3%), and edge-related disease progression (2.6%). Discontinuity (odds ratio [OR]: 110; 95% confidence interval [CI]: 73.5 to 173; p < 0.001), malapposed struts (OR: 17.0; 95% CI: 14.8 to 19.7; p < 0.001), and uncovered struts (OR: 7.3; 95% CI: 6.2 to 8.8; p < 0.001) were more frequent in the thrombosed than the nonthrombosed scaffold regions. In 2 of 16 patients with scaffold discontinuity, intercurrent OCT before VLScT provided evidence of circularly apposed scaffold struts with minimal tissue coverage. CONCLUSIONS: The leading mechanism underlying VLScT was scaffold discontinuity, which suggests an unfavorable resorption-related process, followed by malapposition and neoatherosclerosis. It remains to be determined whether modifications in scaffold design and optimized implantation can mitigate the risk of VLScT. (Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis [INVEST]; NCT03180931).
引用
- Yamaji K, Ueki Y, Souteyrand G, et al. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. J Am Coll Cardiol. 2017. PMID: 29096803. doi:10.1016/j.jacc.2017.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。